***The manuscript*** *should not exceed 6,000 words (for* ***all*** *sections).*

Review

**Title of the Case Report in English: a Review (or a Systematic Review)**

**A Self-Sufficient and Precise Title**

**(not exceeding 13 words, reflecting the goal, including min. 1-2 key words over the first 65 characters, study type at the end divided with a colon, e.g. “Review” or “Systematic Review”)**

**Elena V. Ivanova1,**🖂**, Maria A. Petrova1,2, Marina N. Smirnova1, Vasily G. Sidorov2**

1Scientific Centre for Expert Evaluation of Medicinal Products,

8/2 Petrovsky Blvd, Moscow 127051, Russian Federation

2 Lomonosov Moscow State University,

1/3 Leninskie Gory, Moscow 119991, Russian Federation

🖂 **Elena V. Ivanova** [ivanova@expmed.ru](mailto:ivanova@expmed.ru)

**ABSTRACT.** *The abstract should include as much of manuscript data as possible (150-300 words).*

**INTRODUCTION.** Add 1 to 3 sentences justifying the need to publish this case report. Make sure to include area-specific terms in the first sentences (for SEO optimization).

**AIM.** Make your study question as clear and detailed as possible. Try to clarify the idea of the analysis, and the result(s) that the authors were trying to obtain. Add possible application of your result(s). Your aim should reflect the aim in the text. See AIM for more details.

**DISCUSSION.** The longest part of your Abstract, it reflects important data from each part of the manuscript text. Add specific literature data (when possible, with numbers): what was detected/ found/ determined when reviewing scientific literature or regulatory documents. Critical analysis and summary is crucial; do not just list the past studies.

**CONCLUSIONS.** Conclusions should match study aim and objectives. Add only conclusions directly confirmed by the results. You are welcome to add possible analysis constraints; clinical/ practical significance; and recommend further research.

Make sure you choose specific terminology (in BrE). Transliterarion from Russian into English is allowed only for proper names, devices and other objects that cannot be translated. Make sure you use the same terms all over the text. Active Voice is preferred over Passive Voice, i.e. “The study tested”, not “It was tested in this study”.

**Keywords:** translate your keywords from Russian into English; check out your keywords in [MeSH on Demand](https://meshb.nlm.nih.gov/MeSHonDemand) (to make sure you chose correct wording)

**For citation:** Ivanova E.V., Petrova M.A., Smirnova M.N., Sidorov V.G. Manuscript title in English. *Safety and Risk of Pharmacotherapy.* 2025;13(\_).

**Funding.** *Examples:*

This study was conducted by the Scientific Centre for Expert Evaluation of Medicinal Products as part of the applied research funded under State Assignment No. \_\_\_ (R&D Registry No. \_\_\_).

The study was performed without external funding.

**Disclosure.** *Examples:*

The authors declare having no conflict of interest.

Elena V. Ivanova has been a member of the Editorial Board of *Safety and Risk of Pharmacotherapy* since 2021. The other authors declare having no conflict of interest.

The authors work for Bacteriophage JSC. However, when writing this paper, the authors were guided by considerations of the scientific value of the material obtained; the authors declare their impartiality in its assessment.

**INTRODUCTION**

The introduction should describe scientific relevance of the research topic (i.e. the degree of importance of this topic at this time and in this particular situation). The introduction should establish the research problem, show the scope of this problem, and describe initial hypotheses (if any). Make sure to identify the research gap through a review of previously published data (in Russia and internationally). When explaining the importance of their research, the authors should include significant premises that prove the need to study the selected topic. The authors should answer why they conducted the review, what pressing issue they were trying to solve, and why it was necessary to study this problem at the very moment they did it.

The data should not be overly historical; better avoid using data not related to your study subject or broader than your subject (a common mistake).

Every citation should have its reference. It is not recommended to place a large block of citations at the end of a paragraph with several statements: cite each statement separately. All references to indexed sources (e.g. research papers and monographs) should be identified by consecutive Arabic numerals in square brackets (e.g. [1, 2], [3–7]). Non-indexed sources should be referenced in footnotes (MS Word’s Insert/Footnote function).[[1]](#footnote-1) Non-indexed sources include but are not limited to theses and thesis summaries, educational and instructional materials, legal and regulatory documents (e.g. pharmacopoeia chapters and monographs), standards (e.g. GOSTs), guidelines and recommendations, websites, statistical documentation, scientific and technical documentation (e.g. R&D reports), etc. For further information on the format of footnotes and references, please see the [Author Guidelines](https://www.risksafety.ru/jour/about/submissions#authorGuidelines).

The introduction should not exceed 20% of the article.

The aim of a review could be to systematise/ to classify/ to identify blank spots and knowledge gaps/ to make a roadmap (trend estimation)/ to prove the author’s hypothesis/ or to form a concept. Do not just state the facts and the current question. Make sure to describe practical application of your results. To formulate the aim, answer the following question: What do you want to achieve as a result of the research?

The aim statement should be clear, brief (one- or two-sentence long), and unambiguous (i.e. not open to double interpretation). Avoid using abbreviations. In Russian, it is preferable to use nouns (e.g. evaluation, comparison, development) rather than verbs (e.g. to assess, to analyse, to evaluate).

After the aim, the text should list all the searched databases, libraries, registers, etc.; the period covered by the search; the keywords and filters (if any); and the inclusion and exclusion criteria for the articles to be reviewed. You are highly welcome to show your search strategy schematically, showing your steps and references chosen.

If you used AI to write your manuscript, make sure to add software name, version, and query criteria.

*Example:* While working on this study, the author(s) used [SOFTWARE/ SERVICE NAME] in order to [OBJECTIVE]. The author(s) checked and post-edited the text as necessary and are fully responsible for the content.

**MAIN PART**

When drafting the main body of a review, always keep your aim in mind. Describe the most significant specific ideas and results of the previous research (precise numbers are extremely welcome; you can give a short description of study conditions; avoid general speculations). Show the current state of knowledge for your research question, critically analyse the ideas and find out the patterns.

Make your materials structured using sections and subsections (no numbering needed).

The number of references per a review should not be less than 40. Cite the references published over the last five years in Russia and other countries. If you use only Russian or foreign references, you will need to justify your choice.

Study findings may be presented as tables *(Table 1)* or figures *(Fig. 1)*. For tables and figures, the titles, captions, contents, and notes should be provided in Russian and in English. All the abbreviations used in a table or figure should be written out in full in the note for that table or the caption for that figure, even if this has already been done elsewhere in the text. Tabulated data should not duplicate the information given in figures, and *vice versa*. No full stop is used at the end of the title.

Show your results as patterns identified. Avoid repeating the contents of tables and figures in your text.

Try avoiding abbreviations in your tables and figures; if they are indispensable, decipher them in the notes, even if these abbreviations are in the manuscript text. The table should not have any empty cells. Always state the authorship under the figure/ table (see examples for *Table 1* and *Figure 1*). Add the authorship under the table/ figure (see examples under *Table 1* and *Figure 1*).

**Table 1.** Detailed and self-contained table name

|  |  |  |
| --- | --- | --- |
| ***Heading of column 1*** | ***Heading of column 2*** | ***Heading of column 3*** |
| *Text* | 0.25\* | – |
| 1 | 3 |
| 6 | *Conforms* |

The table is prepared by the authors

The table is prepared by the authors using their own data

The table is reproduced from [1] under CC BY

The table is adapted from [1]

The table is reproduced from the regulatory document

*Note.* If the table contains abbreviations, the abbreviations should be written out in full in the note to the table. If the table contains dashes, their meaning should be explained: –, no data (not applicable, not detected, etc.).

\* Explanations for individual results in the table.

The figure is prepared by the authors

The figure is prepared by the authors using their own data

The figure is reproduced from [1] under CC BY

The figure is adapted from [1]

The photo is taken by the authors

**Fig. 1.** Title of the figure in English

Make sure you use figures and tables from other sources only when it is fully justified. Always state the reference where you borrow from and the license. If it is not a CC BY license, send us a document where the copyright holder allows to publish these figures/ tables.

Please email us a separate document with the illustrations (if these are graphs and diagrams, choose an editable format). Add the names of the axes and measurement units to the graphs and diagrams (in Russian and in English). 2D is preferred over 3D; avoid using circular histograms. When choosing colours for your figures, keep in mind the colour-blind users (e.g. use hatching or introduce figures/letters/symbols to name curves/columns of different colours).

Vector format is preferred for the pictures (it gives higher printed quality and is better indexed with *Academic SEO* – resulting in better visibility and more citations). If you choose bitmap images (e.g. photos, scanned pictures, or screenshots), make sure the resolution is 300 dpi, not compressed. Example of science illustration tools: basic [Microsoft PowerPoint (SmartArt)](https://www.microsoft.com/ru-ru/microsoft-365/powerpoint?market=ru), as well as [bioRENDER](https://www.biorender.com/), [MagicPlot](https://magicplot.com/), [Easel.ly](https://easel.ly/), [Piktochart.com](https://piktochart.com/), and [Venngage.com](https://venngage.com/).

**CONCLUSIONS**

The authors should briefly describe main results, reflecting possible contraints of the analysis; theoretical and practical significance; and recommendation for further research. It is advisable to outline directions for further research in the field.

The conclusion should not repeat the text of the article word for word or reference any literature, as the authors should describe the results of their own analysis.

This section may be formatted as a numbered list of conclusions. In this case, its title should be changed to CONCLUSIONS.

**References**

1. Engalycheva GN, Syubaev RD. WoE Analysis and key risk factors in preclinical development of medicinal products: A review. *Safety and Risk of Pharmacotherapy*. 2024;12(4):463–76 (In Russ.).

<https://doi.org/10.30895/2312-7821-2024-12-4-463-476>

2. Nechaev AV, Leshina SA, Klepikova AG, et al. Adverse reactions to intravenous immunoglobulin therapy: An analysis of the Russian national pharmacovigilance database. *Safety and Risk of Pharmacotherapy*. 2024;12(4):420–31 (In Russ.).

<https://doi.org/10.30895/2312-7821-2024-12-4-420-431>

3. Volynets GV, Nikitin AV, Skvortsova TA, Kokiashvili VS. Drug-induced autoimmune-like hepatitis. *Russian Journal of Evidence-Based Gastroenterology*. 2024;13(1):58–65 (In Russ.).

<https://doi.org/10.17116/dokgastro20241301158>

4. De VA, Zagorodnikova KA, Ivaschenko DV, et al. *Drug-induced diseases*. T. 1. Moscow: Prometey; 2022 (In Russ.). EDN [HICFSZ](https://elibrary.ru/hicfsz)

5. Pecoraro C, Fioretti T, Perruno A, et al. *De novo* large deletions in the PHEX gene caused X-linked hypophosphataemic rickets in two Italian female infants successfully treated with burosumab. *Diagnostics (Basel).* 2023;13(15):2552.

<https://doi.org/10.3390/diagnostics13152552>

6. Rodriguez-Vega G, Perez-Fernandez J, Hidalgo J. *Critical care administration*. New York: Springer; 2020.

<https://doi.org/10.1007/978-3-030-33808-4>

7. Kovalskaya GN, Verlan NV, Mikhalevich EN, Kolmakova ES. *Herbal medicines.* Irkutsk: IGMAPO; 2023 (In Russ.). EDN: [ETMNHW](https://elibrary.ru/etmnhw)

**Additional information.** The authors may provide a link to supplementary materials to the article (figures, tables, and other files), including those placed in a repository (with their digital object identifiers (DOIs)).

**Authors’ contributions.** All the authors confirm that they meet the ICMJE criteria for authorship. The most significant contributions were as follows. *Elena V. Ivanova* conceptualised the study, drafted the manuscript, formulated the conclusions, etc. *Maria A. Petrova* worked with literature sources, etc. *Marina N. Smirnova* drafted the manuscript. *Vasily G. Sidorov* participated in formulating the conclusions and approved the final version of the manuscript for publication.

**Acknowledgements.** The authors express their gratitude to I.I. Ivanov for valuable advice when discussing the study results, to City Hospital No. 3 for granting access to the patient data base, and to Medical University No. 4 for the opportunity to use the special library.

You are not required but mostly welcome to add **Declaration of access to benchmark data and algorithms** according to the journal policy [Access to Research and Study Reproducibility](https://www.risksafety.ru/jour/about/editorialPolicies#custom-10). See [Author Guidelines](https://www.risksafety.ru/jour/about/submissions#authorGuidelines) for templates.

**AUTHORS**

**Elena V. Ivanova,** academic degree, academic status in English

ORCID:https://orcid.org/0000-0000-0000-0000 (Scopus Author ID, Web of Science Researcher ID)

*(Add credentials for each author)*

1. Document title and reference, e.g. OFS.1.2.4.0002.18 Microbiological Quality. State Pharmacopoeia of the Russian Federation, ed. X, v. 1. M.; 2018. [↑](#footnote-ref-1)